13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001274403
Total reported value
$1.1B
$1.1B
11 檔
23.4%
During the Q2 2025 filing period, ARCH Venture Management, LLC (CIK: 0001274403) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $1.1B across 11 reported positions.
In Q2 2025, ARCH Venture Management, LLC displayed an active expansion posture, initiating 3 new positions and adding to 0 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | BEAM | Beam Therapeutics Inc | Stock-Other | 25.82% | -1.82% | — | |
| 2 | VIR | Vir Biotechnology Inc | Stock-Other | 21.76% | -5.33% | — | |
| 3 | MAZE | Maze Therapeutics Inc | Stock-Other | 16.91% | -6.98% | — | |
| 4 | RAPP | Rapport Therapeutics Inc | Stock-Other | 14.19% | -3.11% | — | |
| 5 | ✓ | Verve Therapeutics Inc | Stock-Other | 7.54% | — | — | |
| 6 | LYEL | Lyell Immunopharma Inc | Stock-Other | 5.39% | -5.48% | — | |
| 7 | ERAS | Erasca Inc | Stock-Other | 4.71% | -5.14% | — | |
| 8 | GOSS | Gossamer Bio Inc | Stock-Other | 3.31% | -0.27% | — | |
| 9 | QTTB | Q32 Bio Inc | Stock-Other | 0.16% | -0.30% | EXIT | |
| 10 | UNBX | Unity Biotechnology Inc | Stock-Other | 0.13% | — | — | |
| 11 | CERO | Cero Therapeutics Holdings I | Stock-Other | 0.07% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | VIR | Vir Biotechnology Inc | +21.8% | NEW | New buy |
| 2 | LYEL | Lyell Immunopharma Inc | +5.4% | NEW | New buy |
| 3 | ✓ | Verve Therapeutics Inc | +3.1% | — | Unchanged |
| 4 | CERO | Cero Therapeutics Holdings I | +0.1% | NEW | New buy |
| 5 | ✓ | CERo Therapeutics Holdings Inc | 0% | EXIT | Sold out |
| 6 | QTTB | Q32 Bio Inc | -0.1% | — | Unchanged |
| 7 | UNBX | Unity Biotechnology Inc | -0.4% | — | Unchanged |
| 8 | GOSS | Gossamer Bio Inc | -1% | — | Unchanged |
| 9 | ERAS | Erasca Inc | -2.6% | — | Unchanged |
| 10 | RAPP | Rapport Therapeutics Inc | -4% | — | Unchanged |
| 11 | MAZE | Maze Therapeutics Inc | -5.1% | — | Unchanged |
| 12 | BEAM | Beam Therapeutics Inc | -17.2% | — | Unchanged |
According to official SEC Form 13F filings, ARCH Venture Management, LLC reported a total U.S. public equity portfolio value of $1.1B across 11 disclosed positions in Q2 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including BEAM, VIR, MAZE) accounted for 23.4% of total reported equity market value during Q2 2025.
Top New Position Initiated
VIR
市值: $65.1M
Top Position Liquidated / Trimmed
CERo Therapeutics Holdings Inc
前期市值: $16.1K
During Q2 2025, ARCH Venture Management, LLC's top holdings by market value included BEAM (25.8%)、VIR (21.8%)、MAZE (16.9%). The largest single position, BEAM, represented 25.8% of total portfolio value.
In Q2 2025, ARCH Venture Management, LLC made 4 total portfolio adjustments, initiating 3 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 1 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.